China $46 Billion Jiangsu Hengrui Pharmaceuticals to Raise $1.2 Billion in Hong Kong Secondary Listing IPO, Originally Founded as China State-Owned Lianyungang Pharmaceutical Factory in 1970, IPO on Shanghai Stock Exchange in 2000
Caproasia.com | The leading source of data, research, information & resource for financial professionals, investment managers, professional investors, family offices & advisors to institutions, billionaires, UHNWs & HNWs. Covering capital markets, investments and private wealth in Asia. How do you invest $3 million to $300 million? How do you manage $20 million to $3 billion of assets? Caproasia - Learn more
2025 Summits in Hong Kong & Singapore
Investment / Alternatives Summit - March / Oct / Nov
Investment Day - March / July / Sept / Oct / Nov
Private Wealth Summit - April / Oct / Nov
Family Office Summit - April / Oct / Nov
View Events | Register
This site is for accredited investors, professional investors, investment managers and financial professionals only.
You should have assets around $3 million to $300 million or managing $20 million to $30 billion.
China $46 Billion Jiangsu Hengrui Pharmaceuticals to Raise $1.2 Billion in Hong Kong Secondary Listing IPO, Originally Founded as China State-Owned Lianyungang Pharmaceutical Factory in 1970, IPO on Shanghai Stock Exchange in 2000
16th May 2025 | Hong Kong
China Jiangsu Hengrui Pharmaceuticals ($46 billion market value) is raising$1.2 billion in Hong Kong secondary listing IPO. In 2025 January, China Jiangsu Hengrui Pharmaceuticals filed for a Hong Kong secondary IPO.Jiangsu Hengrui Pharmaceuticals was originally founded as a China state-owned enterprise Lianyungang Pharmaceutical Factory in 1970.Jiangsu Hengrui Pharmaceuticals IPO on Shanghai Stock Exchange in 2000.Profile – Hengrui Pharma is a leading global pharmaceutical company committed to promoting a healthier life for humankind through advancements in science. Hengrui Pharma has been on the Pharma Exec’s annual listing of the top 50 global pharmaceutical companies for the fifth consecutive year. With an established portfolio of high-quality medicines and an extensive pipeline of first-in-class and best-in-class assets across multiple therapeutic areas including oncology, diabetes, cardiovascular, autoimmune and respiratory, Hengrui Pharma is focused on innovation to benefit patients globally. We have 14 R&D centers of excellence in Lianyungang, Shanghai, the U.S. and Europe, 8 major manufacturing sites, and leading technology platforms supported by a dedicated R&D team of more than 5,000 professionals that enable us to accelerate drug development. Hengrui Pharma maximizes the impact of its innovation by collaborating with global partners to address unmet medical needs and improve the lives of patients in China and around the world.
“ China $46 Billion Jiangsu Hengrui Pharmaceuticals to Raise $1.2 Billion in Hong Kong Secondary Listing IPO, Originally Founded as China State-Owned Lianyungang Pharmaceutical Factory in 1970, IPO on Shanghai Stock Exchange in 2000 “
The 2025 Investment Day
Hong Kong | Singapore
March / July / Sept / Oct / Nov
Private Equity, Hedge Funds, Boutique Funds, Private Markets & more. Join 20+ CIOs & Senior investment team, with > 60% single family offices with $300 million AUM. Taking place in Hong Kong and in Singapore. Every March, July, Sept, Oct & Nov.
Visit | Register here
The 2025 Family Office Summit10th April & 16th Oct Hong Kong Ritz Carlton | 24th April & 6th Nov Singapore Amara Sanctuary Resort
Join 80 single family offices & family office professionals in Hong Kong & Singapore
Links: 2025 Family Office Summit | Register here
2025 Investment / Alternatives Summit
March / Oct / Nov in Hong Kong & Singapore
Join leading asset managers, hedge funds, boutique funds, private equity, venture capital & real estate firms in Hong Kong, Singapore & Asia-Pacific at the Investment / Alternatives Summit. Join as delegate, speaker, presenter, partner & sponsor.
Visit | Register here
2025 Private Wealth Summit
April / Oct / Nov in Hong Kong & Singapore
Join CEOs, CIOs, Head of Private Banking, Head of Family Offices & Product Heads at The Private Wealth Summit. Join as delegate, speaker, presenter, partner & sponsor.
Visit | Register here
China $37 Billion Jiangsu Hengrui Pharmaceuticals Files for Hong Kong Secondary IPO, Originally Founded as China State-Owned Lianyungang Pharmaceutical Factory in 1970, IPO on Shanghai Stock Exchange in 2000
Jiangsu Hengrui Pharmaceuticals
14th January 2025 – China Jiangsu Hengrui Pharmaceuticals ($37 billion market value) has filed for a Hong Kong secondary IPO. Jiangsu Hengrui Pharmaceuticals was originally founded as a China state-owned enterprise Lianyungang Pharmaceutical Factory in 1970. Jiangsu Hengrui Pharmaceuticals IPO on Shanghai Stock Exchange in 2000.Hengrui Pharma is a leading global pharmaceutical company committed to promoting a healthier life for humankind through advancements in science. Hengrui Pharma has been on the Pharma Exec’s annual listing of the top 50 global pharmaceutical companies for the fifth consecutive year. With an established portfolio of high-quality medicines and an extensive pipeline of first-in-class and best-in-class assets across multiple therapeutic areas including oncology, diabetes, cardiovascular, autoimmune and respiratory, Hengrui Pharma is focused on innovation to benefit patients globally. We have 14 R&D centers of excellence in Lianyungang, Shanghai, the U.S. and Europe, 8 major manufacturing sites, and leading technology platforms supported by a dedicated R&D team of more than 5,000 professionals that enable us to accelerate drug development. Hengrui Pharma maximizes the impact of its innovation by collaborating with global partners to address unmet medical needs and improve the lives of patients in China and around the world.
Managing $20 million to $3 billion. Investing $3 million to $300 million.
For Investment Managers, Hedge Funds, Boutique Funds, Private Equity, Venture Capital, Professional Investors, Family Offices, Private Bankers & Advisors, sign up today. Subscribe to Caproasia and receive the latest news, data, insights & reports, events & programs daily at 2 pm.
Join Events & Find Services
Join Investments, Private Wealth, Family Office events in Hong Kong, Singapore, Asia-wide. Find hard-to-find $3 million to $300 million financial & investment services at The Financial Centre | TFC. Find financial, investment, private wealth, family office, real estate, luxury investments, citizenship, law firms & more. List hard-to-find financial & private wealth services.
Have a product launch? Promote a product or service? List your service at The Financial Centre | TFC. Join interviews & editorial and be featured on Caproasia.com or join Investments, Private Wealth, Family Office events. Contact us at [email protected] or [email protected]Caproasia.com | The leading source of data, research, information & resource for financial professionals, investment managers, professional investors, family offices & advisors to institutions, billionaires, UHNWs & HNWs. Covering capital markets, investments and private wealth in Asia. How do you invest $3 million to $300 million? How do you manage $20 million to $3 billion of assets?
